COMP <GO>
SILO vs REVB // EV/EBITDA & P/E VALUATION
Silo Pharma Inc. (NASDAQ) VS. Revelation Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: SILO 1
— REVB 1
■ METRIC PARITY
LAST: $1.25 (-6.72%) • MKT CAP: $2.4M
valuation
—
LAST: $3.75 (+0.81%) • MKT CAP: $2.1M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SILO VS. REVB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SILO | REVB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 38.60% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 0.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.1 | 39.7 | -5.52 | REVB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.4M | $2.1M | $245.1K | SILO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SILO REV | REVB REV | SILO GROSS % | REVB GROSS % | SILO FCF | REVB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $72.1K | $0 | 38.6% | — | -$4.7M | -$8.3M |
| FY 2024 | $72.1K | $0 | 91.9% | — | -$3.8M | -$18.3M |
| FY 2023 | $72.1K | $0 | — | — | -$3.2M | -$7.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SILO // BETA —
REVB // BETA —